Westfield Capital Management Co. LP Purchases 80,783 Shares of Haemonetics Co. (NYSE:HAE)

Westfield Capital Management Co. LP increased its position in shares of Haemonetics Co. (NYSE:HAE) by 10.9% during the third quarter, HoldingsChannel reports. The fund owned 823,663 shares of the medical instruments supplier’s stock after buying an additional 80,783 shares during the quarter. Westfield Capital Management Co. LP’s holdings in Haemonetics were worth $66,206,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Quarry LP acquired a new stake in shares of Haemonetics during the second quarter valued at about $39,000. Daiwa Securities Group Inc. acquired a new stake in Haemonetics during the 2nd quarter worth approximately $82,000. Canada Pension Plan Investment Board bought a new stake in Haemonetics during the 2nd quarter worth approximately $83,000. Nisa Investment Advisors LLC grew its holdings in Haemonetics by 124.2% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier’s stock worth $92,000 after acquiring an additional 632 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Haemonetics in the 2nd quarter valued at approximately $140,000. Institutional investors own 99.67% of the company’s stock.

Analyst Ratings Changes

HAE has been the topic of several analyst reports. Barrington Research reissued an “outperform” rating and issued a $108.00 price objective on shares of Haemonetics in a research note on Friday, November 8th. Needham & Company LLC reissued a “buy” rating and issued a $112.00 price target on shares of Haemonetics in a research note on Friday, November 15th. Bank of America began coverage on Haemonetics in a research report on Wednesday, September 11th. They set a “neutral” rating and a $85.00 price objective for the company. CL King began coverage on Haemonetics in a report on Friday, September 13th. They issued a “buy” rating and a $116.00 target price on the stock. Finally, JMP Securities restated a “market outperform” rating and set a $125.00 price target on shares of Haemonetics in a report on Tuesday, August 13th. Three investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $107.88.

Haemonetics Trading Up 0.1 %

Shares of HAE stock opened at $85.55 on Friday. The company has a market cap of $4.30 billion, a P/E ratio of 35.50, a PEG ratio of 1.33 and a beta of 0.32. Haemonetics Co. has a fifty-two week low of $70.25 and a fifty-two week high of $97.97. The stock has a 50 day simple moving average of $78.75 and a two-hundred day simple moving average of $82.40. The company has a debt-to-equity ratio of 1.39, a quick ratio of 2.09 and a current ratio of 3.49.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.03. The company had revenue of $345.50 million during the quarter, compared to analyst estimates of $342.57 million. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. Haemonetics’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.99 EPS. Research analysts forecast that Haemonetics Co. will post 4.59 earnings per share for the current year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.